We were looking for public data on a tight deadline to make decisions on our backup targets for solid tumors. Elucidata was able to understand our relevance criteria, identify, and deliver high-quality harmonized data ahead of schedule.

Elucidata's solutions helped us deepen our understanding of neoantigen-reactive T cells, advancing our T-cell-based anti-tumor therapies. Collaborating with Elucidata enabled crucial insights within six months, offering a clear direction on how to best develop these complex therapeutics

By building a high-quality dataset using harmonized single-cell and bulk RNA-seq data, Elucidata advanced target discovery and lowered preclinical toxicity risks - with results 7× faster than our internal timeline.

"By streamlining data ingestion, processing, and analysis for AML research, Elucidata eliminated inefficiencies, ensured seamless scalability, and saved $1.34M in compute costs."

Extremely impressed by Polly and its power to digest and integrate large datasets. The unique partnership that we have allows us to work hand-in-hand with software engineers and scientists to rapidly develop novel hypotheses that we can test in the lab.